Ironwood Pharmaceuticals Inc. (IRWD) Receives $15.44 Consensus Target Price from Analysts
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) has earned a consensus recommendation of “Hold” from the thirteen ratings firms that are presently covering the stock. Seven analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $15.44.
Several research firms recently weighed in on IRWD. BTIG Research reissued a “buy” rating and set a $18.00 price objective (up previously from $15.00) on shares of Ironwood Pharmaceuticals in a research report on Friday, September 23rd. Mizuho cut their price target on Ironwood Pharmaceuticals from $24.00 to $19.00 and set a “buy” rating for the company in a report on Monday, October 10th. WallachBeth Capital upped their price target on Ironwood Pharmaceuticals from $15.00 to $17.00 and gave the company a “hold” rating in a report on Tuesday, September 27th. Zacks Investment Research cut Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, September 20th. Finally, Barclays PLC upped their price target on Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the company an “equal weight” rating in a report on Friday, August 5th.
Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 16.75 on Monday. The firm’s 50-day moving average price is $14.60 and its 200-day moving average price is $13.34. The firm’s market cap is $2.45 billion. Ironwood Pharmaceuticals has a 12 month low of $7.35 and a 12 month high of $16.89.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. Ironwood Pharmaceuticals had a negative return on equity of 94.17% and a negative net margin of 34.29%. The business earned $66 million during the quarter, compared to analysts’ expectations of $60.01 million. During the same quarter in the previous year, the firm earned ($0.25) EPS. The firm’s revenue was up 66.7% compared to the same quarter last year. Equities research analysts predict that Ironwood Pharmaceuticals will post ($0.76) earnings per share for the current year.
In related news, Director Lawrence S. Olanoff sold 3,200 shares of the stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $13.72, for a total transaction of $43,904.00. Following the sale, the director now directly owns 29,305 shares in the company, valued at approximately $402,064.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.17% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the company. Cadian Capital Management LP acquired a new stake in Ironwood Pharmaceuticals during the third quarter worth approximately $1,588,000. Acrospire Investment Management LLC raised its stake in Ironwood Pharmaceuticals by 20.0% in the third quarter. Acrospire Investment Management LLC now owns 7,800 shares of the company’s stock worth $124,000 after buying an additional 1,300 shares during the period. Principal Financial Group Inc. raised its stake in Ironwood Pharmaceuticals by 1.1% in the third quarter. Principal Financial Group Inc. now owns 23,025 shares of the company’s stock worth $366,000 after buying an additional 256 shares during the period. Spark Investment Management LLC raised its position in shares of Ironwood Pharmaceuticals by 64.1% in the third quarter. Spark Investment Management LLC now owns 568,100 shares of the company’s stock worth $9,021,000 after buying an additional 222,000 shares during the last quarter. Finally, Emerald Acquisition Ltd. raised its position in shares of Ironwood Pharmaceuticals by 60.6% in the third quarter. Emerald Acquisition Ltd. now owns 29,640 shares of the company’s stock worth $471,000 after buying an additional 11,188 shares during the last quarter. Institutional investors and hedge funds own 93.97% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.
Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.